Tag: Dostarlimab
-
Clinical Phases of Drug Development: Dostarlimab combination facilitates promising lung cancer survival.
The Phase II trial of the PD-1 inhibitors for non-squamous non-small cell lung cancer suggested that there are chances of getting a positive outcome with the survival rates of the lung cancer patients.
-
Clinical Phases of Drug Development: Dostarlimab combination facilitates promising lung cancer survival
Clinical Phases of Drug Development Among the different clinical phases of drug development, the 2022 European Society for Medical Oncology (ESMO) Immuno-Oncology Congress presents the largest head-to-head trial of using Dostarlimab along with chemo in non-squamous non-small cell lung cancer. The Phase II trial of the PD-1 inhibitors for non-squamous non-small cell lung cancer suggested…